bioAffinity Technologies Unveils Sputum Test Data for Asthma and COPD at CHEST 2026

  • bioAffinity Technologies will present data on a sputum-based test for lung inflammation at CHEST 2026 on October 20.
  • The test measures key cytokines and cell-surface receptors linked to asthma and COPD, including targets of approved biologic therapies.
  • Data show the test can detect multiple inflammatory markers in sputum using flow cytometry and AI.
  • The test is not yet available for clinical or diagnostic use and remains investigational.

bioAffinity Technologies' sputum-based test aims to provide a more detailed picture of lung inflammation, potentially guiding treatment decisions for asthma and COPD. The global asthma therapeutics market is projected to reach $47.6 billion by 2034, driven by the growing range of biologic therapies targeting specific inflammatory pathways. The test could support a precision medicine approach, helping identify patients who may benefit from specific biologic therapies.

Clinical Validation
Whether the test can be validated for clinical use and gain regulatory approval.
Market Adoption
The pace at which the test could be adopted by clinicians for asthma and COPD management.
Competitive Positioning
How bioAffinity Technologies positions this test against existing diagnostic tools in the asthma and COPD space.